Exacerbation Of Asthma — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for exacerbation of asthma. 89 active patents protecting 3 drugs from 2+ originators. First major cliff: 2026. Daily refresh.

3
Approved drugs
89
Active US patents
61/100
Avg vulnerability
—
Annual revenue covered

Originators in Exacerbation Of Asthma

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Pfizer Inc. 70 patents Generic (originally Schering) 19 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating exacerbation of asthma. Each bar = one year. Y-axis scaled to peak year (33 patents).

3
26
8
27
8
28
6
29
2
30
1
32
3
34
7
35
3
36
9
37
4
38
33
39
1
41

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Epipen
epinephrine
 Pfizer Inc. 70 61 — 2026-12-12
Decadron
dexamethasone
 Generic (originally Merck) 15 46 — 2027-12-19
Deltasone
prednisone
 Generic (originally Schering) 4 76 — 2027-08-03

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
8168218 Deltasone method of use 80 2028-01-07
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
9504699 Deltasone method of use 75 2027-08-03
11173209 Epipen method of use 75 2038-02-06
11173209 Epipen method of use 75 2038-02-06
11744895 Epipen method of use 75 2039-02-06
11191838 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06
11717571 Epipen method of use 75 2039-02-06

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
10537585 Decadron formulation 25 2037-12-18
10159683 Decadron formulation 25 2034-05-23
10799642 Decadron formulation 31 2032-05-11
8409606 Decadron formulation 31 2030-05-14
8450287 Decadron formulation 38 2027-12-19
9119876 Epipen formulation 42 2035-03-13
9119876 Epipen formulation 42 2035-03-13
10130592 Epipen formulation 42 2035-03-13
10022502 Decadron method of use 45 2034-06-22
10028965 Decadron method of use 45 2034-05-23

Related